J. Carter Thorne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
J. Carter Thorne has a total of 244 co-authors. Here are the top co-authors by number of shared publications:
- Janet Elizabeth Pope
University of Western Ontario, London, Ontario, Canada
20 shared publications - Vivian P. Bykerk
V.P. Bykerk, MD, Hospital for Special Surgery, Division of Rheumatology, New York, NY, USA
13 shared publications - Claire E. H. Barber
Department of Community Health Sciences Cumming School of Medicine, University of Calgary Calgary Alberta Canada
11 shared publications - Glen Stewart Hazlewood
Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, University of British Columbia, Vancouver, Canada; McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Canada
10 shared publications - Jessica Widdifield
Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health University of Toronto Toronto Canada
10 shared publications - Bindee Kuriya
Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada
9 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Elsevier in Joint Bone Spine
Title: Impact of Coexisting Gout on Disease Activity in Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)
- 31 October 2026
- Published by Elsevier in Joint Bone Spine
Open AccessTitle: Impact of Coexisting Gout on Disease Activity in Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)
- 25 September 2026
- Published by Wiley in Arthritis Care & Research
Defining Difficult‐to‐Treat Rheumatoid Arthritis in Routine Care: Comparative Performance of Published Criteria and Description of Early and Late Difficult‐to‐Treat Rheumatoid Arthritis Phenotypes
Objective: Despite advances in treat‐to‐target strategies, a subset of patients with rheumatoid arthritis (RA) remains refractory to multiple therapies and is classified as having difficult‐to‐treat RA (D2T‐RA). Although EULAR has proposed classification criteria for D2T‐RA, these patients remain variably identified in real‐world practice because of heterogeneous applications. We aimed to compare the preformance of published applications of the EULAR D2T‐RA criteria in a real‐world RA cohort and to determine weather the timing of D2T‐RA development could distinguish early from late D2T‐RA phenotypes. Methods: Using data from the Ontario Best Practices Research Initiative, a longitudinal real‐world RA registry, we evaluated four literature‐derived adaptations of the EULAR D2T‐RA definition among patients initiating their first advanced therapy. These definitions differed in disease activity requirements, follow‐up duration, and treatment count thresholds. We assessed prevalence, agreement between definitions, and explored different temporal anchors for classifying early versus late D2T‐RA. Results: Among 1,121 patients with RA (mean age 56.0 years; 80.7% female; mean disease duration of 8.4 years), 202 (18%) fulfilled at least one of four D2T‐RA definitions. Prevalence varied substantially across definitions, ranging from 5.5% (definition 4) to 11.7% (definition 2). Definitions 1 and 2, which incorporated multiple disease activity measures, identified the largest proportion of patients, whereas definition 4, which is defined solely by initiation of a third advanced therapy, was most restrictive. Overlap between definitions was modest, with only 44% of patients meeting all definitions 1 through 3, whereas definition 4 identified a distinct group with no overlap with the other definitions, suggesting that these classification approaches capture different patient subsets and are not interchangeable. In temporal analyses, anchoring the D2T‐RA onset to the initiation of the first advanced therapy, a two‐year threshold—selected for its clinical relevance and balanced group sizes—classified approximately 40% of patients as early and approximately 60% as late D2T‐RA. Conclusion: The applications of D2T‐RA criteria are not interchangeable and vary widely in patient capture. A two‐year threshold anchored to the first initiation of advanced therapy offered a clinically balanced early–late D2T‐RA framework. Harmonized, multidimensional definitions incorporating disease activity and temporal stratification are needed to improve phenotyping, prognostication, and cross‐study comparability.
- 25 September 2026
- Published by Wiley in Arthritis Care & Research
Defining Difficult‐to‐Treat Rheumatoid Arthritis in Routine Care: Comparative Performance of Published Criteria and Description of Early and Late Difficult‐to‐Treat Rheumatoid Arthritis Phenotypes
Objective: Despite advances in treat‐to‐target strategies, a subset of patients with rheumatoid arthritis (RA) remains refractory to multiple therapies and is classified as having difficult‐to‐treat RA (D2T‐RA). Although EULAR has proposed classification criteria for D2T‐RA, these patients remain variably identified in real‐world practice because of heterogeneous applications. We aimed to compare the preformance of published applications of the EULAR D2T‐RA criteria in a real‐world RA cohort and to determine weather the timing of D2T‐RA development could distinguish early from late D2T‐RA phenotypes. Methods: Using data from the Ontario Best Practices Research Initiative, a longitudinal real‐world RA registry, we evaluated four literature‐derived adaptations of the EULAR D2T‐RA definition among patients initiating their first advanced therapy. These definitions differed in disease activity requirements, follow‐up duration, and treatment count thresholds. We assessed prevalence, agreement between definitions, and explored different temporal anchors for classifying early versus late D2T‐RA. Results: Among 1,121 patients with RA (mean age 56.0 years; 80.7% female; mean disease duration of 8.4 years), 202 (18%) fulfilled at least one of four D2T‐RA definitions. Prevalence varied substantially across definitions, ranging from 5.5% (definition 4) to 11.7% (definition 2). Definitions 1 and 2, which incorporated multiple disease activity measures, identified the largest proportion of patients, whereas definition 4, which is defined solely by initiation of a third advanced therapy, was most restrictive. Overlap between definitions was modest, with only 44% of patients meeting all definitions 1 through 3, whereas definition 4 identified a distinct group with no overlap with the other definitions, suggesting that these classification approaches capture different patient subsets and are not interchangeable. In temporal analyses, anchoring the D2T‐RA onset to the initiation of the first advanced therapy, a two‐year threshold—selected for its clinical relevance and balanced group sizes—classified approximately 40% of patients as early and approximately 60% as late D2T‐RA. Conclusion: The applications of D2T‐RA criteria are not interchangeable and vary widely in patient capture. A two‐year threshold anchored to the first initiation of advanced therapy offered a clinically balanced early–late D2T‐RA framework. Harmonized, multidimensional definitions incorporating disease activity and temporal stratification are needed to improve phenotyping, prognostication, and cross‐study comparability.
- 28 August 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (11) , 2129-2135
Use of parenteral compared with oral glucocorticoids in early rheumatoid arthritis for chance of being off steroids and escalation of therapy at 1 year
- 28 August 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (11) , 2129-2135
Use of parenteral compared with oral glucocorticoids in early rheumatoid arthritis for chance of being off steroids and escalation of therapy at 1 year
- Open Access
- 15 January 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (7) , 720-738
Team-Based Outpatient Rheumatology Care: A Scoping Review of Terminology, Team Composition, and Impact on Advancing the Quintuple Aim
Objective: Team-based models of rheumatology care are increasingly recognized to improve outcomes across the Quintuple Aim, yet the evidence remains fragmented. This scoping review aimed to map the evidence on team-based outpatient rheumatology care across all domains of the Quintuple Aim (population health, patient experience, costs, provider well-being, and health equity). Methods: This scoping review followed Joanna Briggs Institute methodology and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews (PRISMA-ScR) checklist. We searched MEDLINE, Embase, Web of Science, Cochrane CENTRAL, and CINAHL from inception to May 2024. We included peer-reviewed studies comparing outpatient team-based rheumatology care, involving at least 1 rheumatologist and 1 interdisciplinary healthcare provider, to other models of care. Terminology describing care models was examined in relation to reported team composition and outcomes were mapped to the Quintuple Aim targets. Results: The search identified 6139 unique records, of which 76 reports representing 67 studies met inclusion criteria. Team-based models most frequently involved a rheumatologist and a nurse, although team composition varied widely. Terminology used to describe care models was inconsistent, and care delivery descriptions often lacked sufficient detail to allow replication. Most studies focused on clinical outcomes and patient experience, whereas few included economic, equity, or provider-related outcomes. Conclusion: This review highlights wide variation in team composition, collaboration, and terminology in team-based rheumatology care models. Advancing the field will require standardized terminology, detailed reporting of team roles and processes, and rigorous long-term cost-effectiveness evaluations to fully assess impact across all domains of the Quintuple Aim.
- 15 January 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (7) , 720-738
Open AccessTeam-Based Outpatient Rheumatology Care: A Scoping Review of Terminology, Team Composition, and Impact on Advancing the Quintuple Aim
Objective: Team-based models of rheumatology care are increasingly recognized to improve outcomes across the Quintuple Aim, yet the evidence remains fragmented. This scoping review aimed to map the evidence on team-based outpatient rheumatology care across all domains of the Quintuple Aim (population health, patient experience, costs, provider well-being, and health equity). Methods: This scoping review followed Joanna Briggs Institute methodology and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews (PRISMA-ScR) checklist. We searched MEDLINE, Embase, Web of Science, Cochrane CENTRAL, and CINAHL from inception to May 2024. We included peer-reviewed studies comparing outpatient team-based rheumatology care, involving at least 1 rheumatologist and 1 interdisciplinary healthcare provider, to other models of care. Terminology describing care models was examined in relation to reported team composition and outcomes were mapped to the Quintuple Aim targets. Results: The search identified 6139 unique records, of which 76 reports representing 67 studies met inclusion criteria. Team-based models most frequently involved a rheumatologist and a nurse, although team composition varied widely. Terminology used to describe care models was inconsistent, and care delivery descriptions often lacked sufficient detail to allow replication. Most studies focused on clinical outcomes and patient experience, whereas few included economic, equity, or provider-related outcomes. Conclusion: This review highlights wide variation in team composition, collaboration, and terminology in team-based rheumatology care models. Advancing the field will require standardized terminology, detailed reporting of team roles and processes, and rigorous long-term cost-effectiveness evaluations to fully assess impact across all domains of the Quintuple Aim.
- 15 January 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (9) , 971-976
Stressful Life Events in the Year Prior to Diagnosis and Associations With Rheumatoid Arthritis Characteristics at Presentation and 1 Year Later
Objective: To evaluate the relationship between major life stressors in the year prior to diagnosis and rheumatoid arthritis (RA) symptoms and function at diagnosis and at 1 year. Methods: Data were from adults with RA in the Canadian Early Arthritis Cohort, a multicenter inception cohort from January 2007 to March 2017 with ≥ 12 months of follow-up. Patients completed questionnaires about stressful life events in the prior year: Health Assessment Questionnaire–Disability Index (HAQ-DI); 12-item Short Form Health Survey; and 11-point rating scales of sleep, fatigue, pain, and patient global assessment (PtGA). Group characteristics were compared with ANOVA or chi-square test, and adjusted multivariable regression models examined the effect of stressors on symptoms and function at 1 year. Results: The 1933 participants were mostly White (87%) women (72%) with a mean age of 55 years; 52% reported ≥ 1 stressors in the year prior to diagnosis. Around diagnosis, patients reporting major stressors had significantly worse mean HAQ-DI, depression, sleep, fatigue, pain, and PtGA, which generally worsened with the type and number of stressors. At 1 year, the odds of depression and disability, and ratings of pain, fatigue, poor sleep, and PtGA generally increased with an increasing number of stressors, though Simplified Disease Activity Index (SDAI) improved similarly among groups. Conclusion: Fifty-two percent of patients with newly diagnosed RA reported stressful life events in the year prior to diagnosis that were associated with worse disability, depression, pain, fatigue, sleep, and well-being, but not SDAI, at diagnosis. Poorer patient-reported outcomes persisted at 1 year despite similar improvements in SDAI. Results highlight the potential independent contributions of environmental and psychological factors in the onset and course of RA.
- 15 January 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (9) , 971-976
Stressful Life Events in the Year Prior to Diagnosis and Associations With Rheumatoid Arthritis Characteristics at Presentation and 1 Year Later
Objective: To evaluate the relationship between major life stressors in the year prior to diagnosis and rheumatoid arthritis (RA) symptoms and function at diagnosis and at 1 year. Methods: Data were from adults with RA in the Canadian Early Arthritis Cohort, a multicenter inception cohort from January 2007 to March 2017 with ≥ 12 months of follow-up. Patients completed questionnaires about stressful life events in the prior year: Health Assessment Questionnaire–Disability Index (HAQ-DI); 12-item Short Form Health Survey; and 11-point rating scales of sleep, fatigue, pain, and patient global assessment (PtGA). Group characteristics were compared with ANOVA or chi-square test, and adjusted multivariable regression models examined the effect of stressors on symptoms and function at 1 year. Results: The 1933 participants were mostly White (87%) women (72%) with a mean age of 55 years; 52% reported ≥ 1 stressors in the year prior to diagnosis. Around diagnosis, patients reporting major stressors had significantly worse mean HAQ-DI, depression, sleep, fatigue, pain, and PtGA, which generally worsened with the type and number of stressors. At 1 year, the odds of depression and disability, and ratings of pain, fatigue, poor sleep, and PtGA generally increased with an increasing number of stressors, though Simplified Disease Activity Index (SDAI) improved similarly among groups. Conclusion: Fifty-two percent of patients with newly diagnosed RA reported stressful life events in the year prior to diagnosis that were associated with worse disability, depression, pain, fatigue, sleep, and well-being, but not SDAI, at diagnosis. Poorer patient-reported outcomes persisted at 1 year despite similar improvements in SDAI. Results highlight the potential independent contributions of environmental and psychological factors in the onset and course of RA.
- Open Access
- 1 December 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (2) , 206-212
“It’s Like a One-Stop-Shop”: A Qualitative Study Exploring Patient Experiences With Interdisciplinary Team–Based Rheumatology Care
Objective: Interdisciplinary team–based models of rheumatology care, where rheumatologists and interdisciplinary healthcare professionals deliver care collaboratively, offer a promising solution to improve integrated care; however, an understanding of patients’ experiences with this approach remains limited. We explored patients’ perspectives on receiving care through an interdisciplinary team–based model. Methods: This was a qualitative study informed by qualitative description. We conducted a secondary analysis of semistructured interviews with patients receiving care through an interdisciplinary model in Ontario, Canada. The interviews explored patients’ experiences with team-based care and its perceived impact on disease management. We inductively coded interview transcripts and constructed themes using thematic analysis. Results: Among 15 participants, 47% were female, 10 (67%) had inflammatory arthritis, 3 (20%) had other inflammatory rheumatic diseases, and 2 (13%) had osteoarthritis. We identified 5 overarching themes: (1) educational empowerment, (2) unhurried thoroughness, (3) responsive care, (4) timely care, and (5) personalized care through multispecialist collaboration. Participants perceived team-based care to offer enhanced access, including prompt appointments and timely responses to phone calls, attributed to the involvement of multiple health professionals. Participants described care as comprehensive and proactive, addressing needs beyond what a rheumatologist alone could provide. Longer consultations enabled thorough assessments, education, and support across all aspects of disease management. Participants valued the integrated “one-stop shop” model, which reduced the number of external referrals and separate appointments. Conclusion: Patients valued interdisciplinary team–based rheumatology care for improving care access and delivering integrated, convenient, comprehensive care that holistically addressed their needs. These results support wider implementation.
- 1 December 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (2) , 206-212
Open Access“It’s Like a One-Stop-Shop”: A Qualitative Study Exploring Patient Experiences With Interdisciplinary Team–Based Rheumatology Care
Objective: Interdisciplinary team–based models of rheumatology care, where rheumatologists and interdisciplinary healthcare professionals deliver care collaboratively, offer a promising solution to improve integrated care; however, an understanding of patients’ experiences with this approach remains limited. We explored patients’ perspectives on receiving care through an interdisciplinary team–based model. Methods: This was a qualitative study informed by qualitative description. We conducted a secondary analysis of semistructured interviews with patients receiving care through an interdisciplinary model in Ontario, Canada. The interviews explored patients’ experiences with team-based care and its perceived impact on disease management. We inductively coded interview transcripts and constructed themes using thematic analysis. Results: Among 15 participants, 47% were female, 10 (67%) had inflammatory arthritis, 3 (20%) had other inflammatory rheumatic diseases, and 2 (13%) had osteoarthritis. We identified 5 overarching themes: (1) educational empowerment, (2) unhurried thoroughness, (3) responsive care, (4) timely care, and (5) personalized care through multispecialist collaboration. Participants perceived team-based care to offer enhanced access, including prompt appointments and timely responses to phone calls, attributed to the involvement of multiple health professionals. Participants described care as comprehensive and proactive, addressing needs beyond what a rheumatologist alone could provide. Longer consultations enabled thorough assessments, education, and support across all aspects of disease management. Participants valued the integrated “one-stop shop” model, which reduced the number of external referrals and separate appointments. Conclusion: Patients valued interdisciplinary team–based rheumatology care for improving care access and delivering integrated, convenient, comprehensive care that holistically addressed their needs. These results support wider implementation.
- 1 December 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (3) , 292-296
A Global Survey of Quinacrine Use in Systemic and Cutaneous Lupus Erythematosus
Objective: Experiences with the antimalarial quinacrine for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) remain underexplored. We evaluated and compared dermatologists’ and rheumatologists’ experiences with quinacrine in managing SLE and/or CLE. Methods: We sent a structured survey to 102 SLE specialists within the Systemic Lupus International Collaborating Clinics (SLICC) and the Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS), and 200 members of the Rheumatologic Dermatology Society (RDS). Participants responded to questions on self-reported quinacrine prescription history, perceived clinical benefit, reasons for drug discontinuation, and barriers to prescribing. Results: A total of 20 dermatologists from RDS and 40 SLICC and CaNIOS members responded to the survey. All RDS participants (100%) had previously prescribed quinacrine, compared to 17/40 (43%) of SLICC/CaNIOS participants. The majority of quinacrine prescribers (100% RDS, 12/17 [71%] SLICC/CaNIOS) had prescribed quinacrine in combination with another antimalarial. Hydroxychloroquine (HCQ) or chloroquine (CQ) intolerance (65% RDS, 47% SLICC/CaNIOS) and HCQ/CQ-related retinal toxicity (50% RDS, 24% SLICC/CaNIOS) were other reasons for prescribing quinacrine. Clinical benefit was reported by 19/20 (95%) of RDS and 12/17 (71%) of SLICC/CaNIOS clinicians, and discontinuations were less frequent among RDS (5/20 [25%] reported none) compared to SLICC/CaNIOS (all 17 reported ≥ 1). Availability and cost of quinacrine were primary prescribing barriers. Conclusion: Surveyed dermatologists and rheumatologists differed in their experience with quinacrine for CLE and SLE, respectively. Availability remains a key barrier to prescribing, underscoring the need to address supply issues and conduct further research to optimize quinacrine use in SLE and CLE.
- 1 December 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (3) , 292-296
A Global Survey of Quinacrine Use in Systemic and Cutaneous Lupus Erythematosus
Objective: Experiences with the antimalarial quinacrine for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) remain underexplored. We evaluated and compared dermatologists’ and rheumatologists’ experiences with quinacrine in managing SLE and/or CLE. Methods: We sent a structured survey to 102 SLE specialists within the Systemic Lupus International Collaborating Clinics (SLICC) and the Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS), and 200 members of the Rheumatologic Dermatology Society (RDS). Participants responded to questions on self-reported quinacrine prescription history, perceived clinical benefit, reasons for drug discontinuation, and barriers to prescribing. Results: A total of 20 dermatologists from RDS and 40 SLICC and CaNIOS members responded to the survey. All RDS participants (100%) had previously prescribed quinacrine, compared to 17/40 (43%) of SLICC/CaNIOS participants. The majority of quinacrine prescribers (100% RDS, 12/17 [71%] SLICC/CaNIOS) had prescribed quinacrine in combination with another antimalarial. Hydroxychloroquine (HCQ) or chloroquine (CQ) intolerance (65% RDS, 47% SLICC/CaNIOS) and HCQ/CQ-related retinal toxicity (50% RDS, 24% SLICC/CaNIOS) were other reasons for prescribing quinacrine. Clinical benefit was reported by 19/20 (95%) of RDS and 12/17 (71%) of SLICC/CaNIOS clinicians, and discontinuations were less frequent among RDS (5/20 [25%] reported none) compared to SLICC/CaNIOS (all 17 reported ≥ 1). Availability and cost of quinacrine were primary prescribing barriers. Conclusion: Surveyed dermatologists and rheumatologists differed in their experience with quinacrine for CLE and SLE, respectively. Availability remains a key barrier to prescribing, underscoring the need to address supply issues and conduct further research to optimize quinacrine use in SLE and CLE.
- Open Access
- 1 October 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (4) , 376-385
Evaluating Implementation Context to Prepare for Scaling Up the Integration of Interdisciplinary Healthcare Providers in Rheumatology Practices: A Rheumatology Workforce Survey
Objective: Interdisciplinary healthcare providers (IHPs) can support effective delivery of optimal rheumatology care. To inform widespread implementation efforts, we assessed rheumatology workforce characteristics and determinants of integrating of IHPs within rheumatology practices in Ontario, Canada. Methods: A convergent mixed methods design included an environmental scan to identify clinically active rheumatologists and a workforce survey guided by the Consolidated Framework for Implementation Research (CFIR) 2.0. Quantitative data were analyzed descriptively and stratified by subgroups. Qualitative responses were analyzed using conventional content analysis. Integration of findings enabled a comprehensive understanding of implementation determinants. Results: Of the 293 Ontario rheumatologists identified by the environmental scan (as of 2025), 26 were nearing retirement, leaving potentially 267 eligible for the survey. One hundred ninety-seven rheumatologists participated in the survey, yielding a response rate of 74% and coverage of > 90% of practice sites. Pediatric rheumatologists and those in hospital-based settings had more structural and collaborative supports than community-based rheumatologists. Overall, 177 (91%) indicated they were interested in adding IHPs, with 126 (65%) preferring an extended role/scope provider. Although inadequate funding was the key deterrent to adoption, motivational readiness was high: 92% perceived an IHP team-based model as an improvement, 86% saw it as a good fit, and 83% considered it a priority to better meet patient needs. Many noted a lack of supportive climate, including that of resources and processes, to enable this practice change. Conclusion: Rheumatologists report high motivation for practice change to integrate IHPs. System- and practice-level implementation strategies are needed to support workforce transformation.
- 1 October 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (4) , 376-385
Open AccessEvaluating Implementation Context to Prepare for Scaling Up the Integration of Interdisciplinary Healthcare Providers in Rheumatology Practices: A Rheumatology Workforce Survey
Objective: Interdisciplinary healthcare providers (IHPs) can support effective delivery of optimal rheumatology care. To inform widespread implementation efforts, we assessed rheumatology workforce characteristics and determinants of integrating of IHPs within rheumatology practices in Ontario, Canada. Methods: A convergent mixed methods design included an environmental scan to identify clinically active rheumatologists and a workforce survey guided by the Consolidated Framework for Implementation Research (CFIR) 2.0. Quantitative data were analyzed descriptively and stratified by subgroups. Qualitative responses were analyzed using conventional content analysis. Integration of findings enabled a comprehensive understanding of implementation determinants. Results: Of the 293 Ontario rheumatologists identified by the environmental scan (as of 2025), 26 were nearing retirement, leaving potentially 267 eligible for the survey. One hundred ninety-seven rheumatologists participated in the survey, yielding a response rate of 74% and coverage of > 90% of practice sites. Pediatric rheumatologists and those in hospital-based settings had more structural and collaborative supports than community-based rheumatologists. Overall, 177 (91%) indicated they were interested in adding IHPs, with 126 (65%) preferring an extended role/scope provider. Although inadequate funding was the key deterrent to adoption, motivational readiness was high: 92% perceived an IHP team-based model as an improvement, 86% saw it as a good fit, and 83% considered it a priority to better meet patient needs. Many noted a lack of supportive climate, including that of resources and processes, to enable this practice change. Conclusion: Rheumatologists report high motivation for practice change to integrate IHPs. System- and practice-level implementation strategies are needed to support workforce transformation.
- Open Access
- 13 September 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 9 (4) , rkaf120
Predictors of depression trajectories during the COVID-19 pandemic in adults with rheumatoid arthritis: results from the Canadian Early Arthritis Cohort
Objectives: Growing evidence points to mental health impacts of coronavirus disease 2019 (COVID-19). We explored trajectories of depressive symptoms in the year pre- and 2 years post-pandemic onset in adults with RA. Methods: Data are from the Canadian Early Arthritis Cohort (CATCH), a prospective, multicentre, early RA cohort of Canadian adults treated by rheumatologists. Pre-pandemic, participants completed patient-reported outcome measures and rheumatology exams in person. After March 2020, patient-reported outcomes were collected at in-person and virtual visits. We used group-based trajectory modelling to explore longitudinal patterns of depressive symptoms prior to and throughout the COVID-19 pandemic and multinomial regression to identify factors associated with depression trajectory group. Results: A total of 989 participants had a mean age of 60 years (s.d. 14), RA for 6 years (s.d. 4) and were mostly white (84%) and female (73%) with some college education (60%). Most (77%) were in Clinical Disease Activity Index remission/low disease activity prior to the pandemic. We identified four trajectories: resilient (no symptoms throughout: 60%), worsening (none–mild: 22%), improving (mild–minimal: 8%) and persistent (moderate–severe throughout: 9%). Age, sex, race, education, pain, physical and social functioning, fibromyalgia and history of anxiety/depression were associated with different trajectories. Conclusion: Although 60% had a consistent affect during the first 2 years of the pandemic, mood worsened in greater than one in five, suggesting a cumulative impact over time. Biological, psychological and social factors and worse pre-pandemic symptoms and function were associated with a greater risk of depression during the pandemic. Identifying at-risk groups impacted by major stressors like the pandemic may offer new opportunities to personalize treatment, allocate resources, reduce disease flares and improve outcomes.
- 13 September 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 9 (4) , rkaf120
Open AccessPredictors of depression trajectories during the COVID-19 pandemic in adults with rheumatoid arthritis: results from the Canadian Early Arthritis Cohort
Objectives: Growing evidence points to mental health impacts of coronavirus disease 2019 (COVID-19). We explored trajectories of depressive symptoms in the year pre- and 2 years post-pandemic onset in adults with RA. Methods: Data are from the Canadian Early Arthritis Cohort (CATCH), a prospective, multicentre, early RA cohort of Canadian adults treated by rheumatologists. Pre-pandemic, participants completed patient-reported outcome measures and rheumatology exams in person. After March 2020, patient-reported outcomes were collected at in-person and virtual visits. We used group-based trajectory modelling to explore longitudinal patterns of depressive symptoms prior to and throughout the COVID-19 pandemic and multinomial regression to identify factors associated with depression trajectory group. Results: A total of 989 participants had a mean age of 60 years (s.d. 14), RA for 6 years (s.d. 4) and were mostly white (84%) and female (73%) with some college education (60%). Most (77%) were in Clinical Disease Activity Index remission/low disease activity prior to the pandemic. We identified four trajectories: resilient (no symptoms throughout: 60%), worsening (none–mild: 22%), improving (mild–minimal: 8%) and persistent (moderate–severe throughout: 9%). Age, sex, race, education, pain, physical and social functioning, fibromyalgia and history of anxiety/depression were associated with different trajectories. Conclusion: Although 60% had a consistent affect during the first 2 years of the pandemic, mood worsened in greater than one in five, suggesting a cumulative impact over time. Biological, psychological and social factors and worse pre-pandemic symptoms and function were associated with a greater risk of depression during the pandemic. Identifying at-risk groups impacted by major stressors like the pandemic may offer new opportunities to personalize treatment, allocate resources, reduce disease flares and improve outcomes.